Why collaboration and an Integrated Product Development program are key to successful drug development

Employee training

Integrated product development (IPD) offers a way to mitigate the many issues that slow down the process of bringing a drug to market. A tendency to think of drug development as sequential and phase-driven means different activities are conducted in functional silos, which adversely affects the process.

In a recent BioProcess International special report, Mark Lane, Vice President of Development Consulting and Scientific Affairs at PharmaLex, explores how a global IPD program drives integrated collaboration and is an essential tool for improving efficiency, shortening timelines, reducing costs and improving the probability of regulatory approval and success in the marketplace. Download the special report to learn more.


The contents of this article/presentation are solely the opinion of the author and do not represent the opinions of PharmaLex GmbH or its parent AmerisourceBergen Corporation. PharmaLex and AmerisourceBergen strongly encourage readers/listeners to review available information related to the topics mentioned herein and to rely on their own experience and expertise in making decisions related thereto.

Scroll to Top